8-K

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

                       AUGUST 30, 2010 (AUGUST 26, 2010)
                DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)

                         COMPETITIVE TECHNOLOGIES, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                                    DELAWARE
                                    --------
                 (STATE OR OTHER JURISDICTION OF INCORPORATION)

                           1-8696          36-2664428
                           ------          ----------
         (COMMISSION FILE NUMBER)     (IRS EMPLOYER IDENTIFICATION NO.)


                777 COMMERCE DRIVE, FAIRFIELD, CONNECTICUT 06825
                ------------------------------------------------
               (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)(ZIP CODE)

                                 (203) 368-6044
                                 --------------
              REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:

                                      N/A
         (FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))



ITEM 3.01.  NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE
OR STANDARD; TRANSFER OF LISTING

On August 30, 2010, Competitive Technologies, Inc. ("CTT") released the press
release attached hereto as Exhibit 99.1, announcing that its common stock is
expected to trade on the Over-the-Counter Bulletin Board  ("OTCBB") after
receiving notification that the NYSE Amex, LLC (the "Exchange") plans to suspend
trading in the Company's common stock effective at the open of trading on
September 3, 2010.

ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

99.1     Press Release.

                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                    COMPETITIVE TECHNOLOGIES, INC.
                                  (Registrant)

Dated: August 30, 2010          By:  \s\ John B. Nano
                                     ----------------
                                John B. Nano
                                Chairman and Chief Executive Officer

EX-99.1

EXHIBIT  99.1

Competitive
Technologies
Unlocking the Potential of Innocation (R)

                                                           For immediate release

          COMPETITIVE TECHNOLOGIES' COMMON STOCK EXPECTED TO TRADE OTC

FAIRFIELD, CT - (AUGUST 30, 2010) - COMPETITIVE TECHNOLOGIES, INC. (NYSE AMEX:
CTT) announced today that its common stock is expected to trade on the
Over-the-Counter Bulletin Board  ("OTCBB") after receiving notification that the
NYSE Amex, LLC (the "Exchange") plans to suspend trading in the Company's common
stock effective at the open of trading on September 3, 2010.  The Company will
follow the formal application procedures and notify investors as soon as
possible of the new trading symbol and the final status of the fund raise with
the Crisnic Fund that was announced June 2, 2010.  The Exchange informed CTT of
its determination, subsequent to the August 25, 2010 oral hearing before the
Exchange's Listing Qualifications Panel, which affirmed the Exchange Staff's
earlier determination to delist the Company's securities from the Exchange
primarily due to continued losses and low equity.

The CTT Board of Directors stated that they are disappointed with the Exchange's
decision; however, are committed to moving the Company toward profitability and
to building a stronger organization going forward.  The Board considers this to
be a temporary situation until the Company has demonstrated continued
profitability from its strong product and looks forward to regaining listing on
a major exchange.

The marketing plan that is now established for the Calmare medical device is
beginning to show success and the product is reaching numerous potential
customers.  The Company continues to receive significant positive feedback as to
the success of the Calmare therapy treatments and these successes are beginning
to drive the market.

The Calmare product is providing the foundation needed to expand into a full
Contract Sales Organization (CSO). As a CSO the company assists inventors and
companies in the sales and marketing of their products and/or services
especially prevalent in the life sciences, medical device, and medical product
launch sectors. The Company is looking to expand its product lines and has leads
on specific products. CTT has a foundation of Sales Reps and will be tapping
every source to provide these Reps with additional products. The Company is not
abandoning its established model but is expanding its business model to be a
stronger sales organization.

Over the next month, the Company will be revisiting its status in the
international markets and determining what changes might need to be implemented
to enhance sales in all of these markets. The Board is not pleased with the
results of some marketing partners and plans to reestablish new marketing
partners where necessary.

ABOUT  COMPETITIVE  TECHNOLOGIES,  INC.

Competitive Technologies, established in 1968, provides distribution, patent and
technology  transfer,  sales  and licensing services focused on the needs of its
customers  and  matching  those requirements with commercially viable product or
technology  solutions.  CTT  is  a  global leader in identifying, developing and
commercializing  innovative products and technologies in life, electronic, nano,
and  physical  sciences  developed by universities, companies and inventors. CTT
maximizes  the  value  of  intellectual assets for the benefit of its customers,
clients  and  shareholders.  Visit  CTT's  website:  www.competitivetech.net
                                                     -----------------------

The  non-invasive  Calmare  pain  therapy device uses the biophysical "Scrambler
Therapy"  technology,  which  was  developed in Italy by CTT's client, Professor
Giuseppe  Marineo.  CTT's  partner,  GEOMC  Co.  Ltd.  of  Seoul,  Korea  is
manufacturing  the  Calmare  device,  which  has U.S. FDA clearance and European
Union  CE  Mark  clearance  for  sales.  For more information about Calmare Pain
Therapy  Treatment,  visit  www.CalmareTT.com.
                            -----------------



Statements made about our future expectations are forward-looking statements and
subject to risks and uncertainties as described in our most recent Annual Report
on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27,
2009, and other filings with the SEC, and are subject to change at any time. Our
actual results could differ materially from these forward-looking statements. We
undertake no obligation to update publicly any forward-looking statement.

Direct inquiries to:  Johnnie D. Johnson,
IR Services, LLC, Tel: 860 434 2465,
E-mail: jdjohnson@corpirservices.com
        ----------------------------